Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1

被引:14
|
作者
Ascione, Alessandro [1 ]
Capecchi, Barbara [2 ]
Campitelli, Laura [3 ]
Imperiale, Valentina [1 ]
Flego, Michela [1 ]
Zamboni, Silvia [1 ]
Gellini, Mara [1 ]
Alberini, Isabella [2 ]
Pittiglio, Eliana [1 ]
Donatelli, Isabella [3 ]
Temperton, Nigel J. [4 ,5 ]
Cianfriglia, Maurizio [1 ]
机构
[1] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy
[2] Novartis Vaccines & Diagnost, I-53100 Siena, Italy
[3] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy
[4] UCL, Wohl Vir Ctr, London W1T 4JF, England
[5] UCL, Div Infect & Immun, London W1T 4JF, England
关键词
Avian influenza; H5N1; virus; Immunoprophylaxis; Neutralizing mAbs; scFv; HEMAGGLUTININ; GENERATION; LIBRARIES; EPITOPES; THERAPY; DESIGN; UPDATE;
D O I
10.1016/j.antiviral.2009.05.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Effective diagnostic and therapeutic strategies are needed to control and combat the highly pathogenic avian influenza virus (AIV) subtype H5N1. To this end, we developed human monoclonal antibodies (mAbs) in single chain fragment variable (scFv) format towards the H5N1 avian influenza virus to gain new insights for the development of immunotherapy against human cases of H5N1. Using a biopanning based approach a large array of scFvs against H5N1 virus were isolated from the human semi-synthetic ETH-2 phage antibody library. H5N1 ELISA-positive scFvs with unique variable heavy (VH) and light (VL) chain gene sequences showed different biochemical properties and neutralization activity across H5N1 viral strains. In particular, the scFv clones AV.D1 and AV.C4 exerted a significant inhibition of the H5N1 A/Vietnam/1194/2004 virus infection in a pseudotype-based neutralization assay. Interestingly. these two scFvs displayed a cross-clade neutralizing activity versus A/whooping swan/Mongolia/244/2005 and A/Indonesia/5/2005 strains. These studies provide proof of the concept that human mAbs in scFv format with well-defined H5N1 recognition patterns and in vitro neutralizing activity can be easily and rapidly isolated by biopanning selection of an entirely artificial antibody repertoire using inactivated H5N1 virus as a bait. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [21] The protective effect of a combination of human intracellular and extracellular antibodies against the highly pathogenic avian influenza H5N1 virus
    Jin, Qiu
    Yao, Zhangyu
    Liu, Fangzhou
    Di, Yaxuan
    Gao, Jun
    Zhang, Xiao
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [22] Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies
    Rimmelzwaan, Guus F.
    Verburgh, R. Joyce
    Nieuwkoop, Nella J.
    Bestebroer, Theo M.
    Fouchier, Ron A. M.
    Osterhaus, Albert D. M. E.
    VACCINE, 2011, 29 (18) : 3424 - 3430
  • [23] Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection
    Itoh, Yasushi
    Yoshida, Reiko
    Shichinohe, Shintaro
    Higuchi, Megumi
    Ishigaki, Hirohito
    Nakayama, Misako
    Van Loi Pham
    Ishida, Hideaki
    Kitano, Mitsutaka
    Arikata, Masahiko
    Kitagawa, Naoko
    Mitsuishi, Yachiyo
    Ogasawara, Kazumasa
    Tsuchiya, Hideaki
    Hiono, Takahiro
    Okamatsu, Masatoshi
    Sakoda, Yoshihiro
    Kida, Hiroshi
    Ito, Mutsumi
    Le Quynh Mai
    Kawaoka, Yoshihiro
    Miyamoto, Hiroko
    Ishijima, Mari
    Igarashi, Manabu
    Suzuki, Yasuhiko
    Takada, Ayato
    PLOS PATHOGENS, 2014, 10 (06)
  • [24] Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy
    Masalova, O. V.
    Klimova, R. R.
    Chichev, E. V.
    Fediakina, I. T.
    Loginova, S. Ya.
    Borisevich, S. V.
    Bondarev, V. P.
    Deryabin, P. G.
    Lvov, D. K.
    Kushch, A. A.
    ACTA VIROLOGICA, 2011, 55 (01) : 3 - 14
  • [25] Absence of neutralizing antibodies against influenza A/H5N1 virus among children in Kamphaeng Phet, Thailand
    Khuntirat, Benjawan
    Love, Christopher S.
    Buddhari, Darunee
    Heil, Gary L.
    Gibbons, Robert V.
    Rothman, Alan L.
    Srikiatkhachorn, Anon
    Gray, Gregory C.
    Yoon, In-Kyu
    JOURNAL OF CLINICAL VIROLOGY, 2015, 69 : 78 - 80
  • [26] A Novel Peptide ELISA for Universal Detection of Antibodies to Human H5N1 Influenza Viruses
    Velumani, Sumathy
    Ho, Hui-Ting
    He, Fang
    Musthaq, Syed
    Prabakaran, Mookkan
    Kwang, Jimmy
    PLOS ONE, 2011, 6 (06):
  • [27] Monoclonal antibodies targeting the synthetic peptide corresponding to the polybasic cleavage site on H5N1 influenza hemagglutinin
    Tsai, Henry J.
    Chi, Li-Ann
    Yu, Alice L.
    JOURNAL OF BIOMEDICAL SCIENCE, 2012, 19
  • [28] An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses
    Shoji, Yoko
    Chichester, Jessica A.
    Palmer, Gene A.
    Farrance, Christine E.
    Stevens, Robert
    Stewart, Michelle
    Goldschmidt, Lauren
    Deyde, Varough
    Gubareva, Larisa
    Klimov, Alexander
    Mett, Vadim
    Yusibov, Vidadi
    HUMAN VACCINES, 2011, 7 : 199 - 204
  • [29] Preparation of vaccines against H5N1 influenza
    Wood, JM
    Major, D
    Newman, RW
    Dunleavy, U
    Nicolson, C
    Robertson, JS
    Schild, GC
    VACCINE, 2002, 20 : S84 - S87
  • [30] Influenza virus A (H5N1): a pandemic risk?
    Babakir-Mina, Muharnmed
    Balestra, Emanuela
    Perno, Carlo Federico
    Aquaro, Stefano
    NEW MICROBIOLOGICA, 2007, 30 (02) : 65 - 78